ACADIA Pharmaceuticals Inc. (ACAD) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en San Diego, CA, United States. El CEO actual es Catherine E. Owen Adams.
ACAD tiene fecha de IPO 2004-05-27, 653 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $3.75B.
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company headquartered in San Diego, California, specializing in the development and commercialization of small molecule drugs for central nervous system disorders. The company's flagship product, NUPLAZID (pimavanserin), is approved for treating hallucinations and delusions associated with Parkinson's disease psychosis. ACADIA's pipeline includes multiple late-stage candidates such as pimavanserin for Alzheimer's disease psychosis and schizophrenia, Trofinetide for Rett syndrome, ACP-044 for acute and chronic pain management, and ACP-319 for cognitive impairment in schizophrenia and Alzheimer's disease. Founded in 1993, ACADIA remains focused on addressing significant unmet medical needs in neuropsychiatric and neurological conditions.
